Revenue Achievement
Reported revenue in Q2 was in the top half of the guidance range for both total revenue and core revenue, with diagnostics growing 3% year-over-year.
Innovation Roadmap Progress
Launched HEMAcollect PROTEIN in July to expand the portfolio with new products, specifically targeting proteomic researchers.
Leadership Addition
Anne Messing joined as Chief Commercial Officer, bringing over 25 years of commercial leadership experience.
Transition to Internal Manufacturing
Completed the transition from external contract manufacturing to internal capabilities ahead of schedule, expected to improve operational efficiencies.
GeneDx Agreement Renewal
Renewed agreement with GeneDx, supporting early diagnosis of rare pediatric diseases through genome analysis.
Colli-Pee Device FDA Submission
Strong progress towards a 2025 FDA submission for the Colli-Pee device, targeting a multibillion-dollar global market.